Viewing Study NCT02574533

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:49 AM
Ignite Modification Date: 2026-03-11 @ 3:41 PM
Study NCT ID: NCT02574533
Status: COMPLETED
Last Update Posted: 2017-09-27
First Post: 2015-10-09
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Sponsor: Gradalis, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma Recurrent View
None Malignant Melanoma View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunotherapy View
None PD-1 inhibitor View
None Keytruda View
None checkpoint inhibitor View
None vaccine View
None FANG View
None Vigil View